Duloxetine compared with placebo for walking in knee osteoarthritis
Tests duloxetine against placebo for walking ability in people with knee osteoarthritis.
Key facts
- Who runs it
- Benedict Alter
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 85 people, planned
- Started
- 15 Sept 2026
- Expected to end
- Mar 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Duloxetine
- Placebo
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term knee pain from knee osteoarthritis. It tests whether duloxetine, compared with a placebo (dummy pill), improves walking and physical activity.
- Age
- 45 to 80 years
- Sex
- Men and women
- Disease stage
- Knee pain for more than 6 months. Moderate-to-severe pain (more than 3/10) from osteoarthritis on more than 50% of days in the past month. KL grade 2-4 changes on knee X-ray.
- Earlier treatment
- No duloxetine in the last 3 months. No current antidepressants or tramadol. No more than 30 mg oral morphine equivalents per day. No new knee osteoarthritis treatment started in the last month. No knee replacement or open surgery on the more painful knee.
Main reasons for not taking part
- Inflammatory arthritis, such as rheumatoid arthritis, or another pain condition that hurts more
- Recent knee steroid injection (within 1 month), or knee radiofrequency ablation or arthroscopic surgery (within 3 months)
- Unable to walk or climb stairs without significant help (a cane is allowed)
- Pregnancy, severe kidney problems (GFR < 30 ml/min), chronic liver disease or cirrhosis, or angle-closure glaucoma
- History of brain surgery, or not able to understand and read English
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Knee pain for greater than 6 months
- Moderate-to-severe knee pain (>3/10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria (Zhang 2010, Altman 1986) on >50% of days in the past month
- KL grade 2-4 (Kellgren and Lawrence 1957) indicating significant degenerative changes on knee X-ray. This will be determined on evaluation of weight-bearing clinical X-rays on review of medical records. In the infrequent situation that the patient does not have an X-ray on review of their medical records, then the patient will obtain weight-bearing knee X-rays as part of the Screening Visit
- Age: 45-80 years old
- Gender: Males and females will be recruited
- Language: only English-speaking subjects will be included
Who cannot take part
- New treatment that may help knee osteoarthritis (including medication, exercise, behavioral, or complementary and integrative treatments) started in the last month. Stable use of treatments for greater than 1 month does not exclude the participant
- Recent knee intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant)
- Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant)
- More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis)
- Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke)
- Unwillingness to maintain current knee osteoarthritis treatments for the duration of the study. This means that eligible participants must plan for the following: medications and dietary supplements should not change substantially in frequency or dose; behavioral therapy, exercise therapy, and complementary and integrative therapies should be consistent; and there should be no interventional treatments planned for lower extremity musculoskeletal conditions (e.g. joint steroid injections, knee radiofrequency ablation, knee replacement surgery)
- History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month
- Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English)
- Uncontrolled or unstable medical disorder preventing participation in study procedures
- History of brain surgery
- History of chronic liver disease or cirrhosis
- History of angle-closure glaucoma
- History of severe renal impairment defined by GFR < 30 ml/min or, if renal function testing is not available on EMR review, patient-reported history of acute or chronic kidney disease of any severity
- Inflammatory arthritis (e.g. rheumatoid arthritis)
- New, ongoing acute pain
- Recent use of duloxetine defined as any use within the last 3 months
- Current use of antidepressants or tramadol
- Current routine use of more than 30 mg oral morphine equivalents per day (use of <=30 mg OME does not exclude the participant)
- Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant)
- Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheelchair; use of a cane does not exclude the participant)
- Tattoos on sensory testing sites
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Where in United States
- University of Pittsburgh - Center for Innovation in Pain Care (Research)Pittsburgh, United StatesContact: Benedict Alter, MD, PhDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to examine the effects of duloxetine on walking ability and physical activity in patients with knee osteoarthritis. Researchers will compare duloxetine to a placebo (a look-alike substance that contains no drug) to see if duloxetine works to improve walking ability in patients with knee osteoarthritis. At study visits, participants will complete surveys, perform physical function tasks, undergo non-invasive brain imaging, and undergo sensory testing.
The 2 groups in the trial
- Duloxetine, then placeboTreatment being tested
In Period A, participants will receive duloxetine. In Period B, participants will receive placebo.
Treatment: Duloxetine and Placebo
- Placebo, then duloxetineTreatment being tested
In Period A, participants will receive placebo. In Period B, participants will receive duloxetine.
Treatment: Duloxetine and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance
- Plain-language title
- Duloxetine compared with placebo for walking in knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07759336, who can take part
- Record updated
- 21 October 2026